Ginkgo Bioworks DNA Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Ginkgo Bioworks in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Ginkgo Bioworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ginkgo Bioworks's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ginkgo Bioworks's cash & equivalents?
- Ginkgo Bioworks (DNA) reported cash & equivalents of $188.67M in Q1 2026.
- How has Ginkgo Bioworks's cash & equivalents changed year-over-year?
- Ginkgo Bioworks's cash & equivalents decreased by 46.9% year-over-year, from $355.41M to $188.67M.
- What is the long-term trend for Ginkgo Bioworks's cash & equivalents?
- Over 5 years (2020 to 2025), Ginkgo Bioworks's cash & equivalents has grown at a -11.3% compound annual growth rate (CAGR), from $385.88M to $212.37M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.